CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer: two case reports
Jin Ho Baek
J Yeungnam Med Sci. 2022;39(1):62-66.   Published online April 19, 2021
DOI: https://doi.org/10.12701/yujm.2021.00934

Excel Download

Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer: two case reports
Journal of Yeungnam Medical Science. 2022;39(1):62-66   Crossref logo
Link1 Link2 Link3

A Case Report of Graves’ Disease Induced by the Anti-Human Programmed Cell Death-1 Monoclonal Antibody Pembrolizumab in a Bladder Cancer Patient
Case Reports in Endocrinology. 2019;2019:1-5   Crossref logo
Link1 Link2 Link3

Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
Cancer Chemotherapy and Pharmacology. 2013;72(2):397-403   Crossref logo
Link1 Link2 Link3

Surgical Treatment of Initially Unresectable Locally Advanced Non-small Cell Lung Cancer Following Tislelizumab Plus Chemotherapy: A Case Report
. 2021;   Crossref logo
Link1 Link2

Nivolumab/sitravatinib/tislelizumab
Reactions Weekly. 2021;1847(1):365-365   Crossref logo
Link1 Link2 Link3

Long-Term Survival of Two Patients with Liver Metastases from Advanced Gastric Cancer Treated with Radiofrequency Ablation and Chemotherapy
Case Reports in Oncology. 2021;14(1):67-72   Crossref logo
Link1 Link2

Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma
Thoracic Cancer. 2020;11(12):3419-3421   Crossref logo
Link1 Link2 Link3

Phase I/II study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody BGB-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors
Annals of Oncology. 2018;29:viii146   Crossref logo
Link1 Link2 Link3

Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer
Cancer Treatment Reviews. 2020;85:101979   Crossref logo
Link1 Link2

Effect of Post-Protocol Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal AntiBody (MAB) Therapy on Survival Outcomes in Patients with Wild-Type (WT) Kras Metastatic Colorectal Cancer (MCRC) Treated with Panitumumab (PMAB) Plus Chemotherapy
Annals of Oncology. 2012;23:ix194-ix195   Crossref logo
Link1 Link2